Join
Live feed
·
PRReleasevia Quantisnow
Coherus Oncology Inc. logo

Coherus Presents Promising Early Clinical Data from Phase 1 Dose Expansion Study of CHS-114 in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma at AACR 2025

ByQuantisnow·Wall Street's wire, on your screen.
CHRS· Coherus Oncology Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track CHRS (Coherus Oncology Inc.) and more on Quantisnow.